Cambridge Healthtech Institute’s Inaugural
Vector Design and Development for Gene and Cell Therapies
Engineering Safer and More Efficacious Vectors
January 20-21, 2020
Part of the Cell & Gene Therapies pipeline
The recent success in gene and cell therapies has necessitated a resurgence in vector engineering. Research and development efforts focusing on vectors to combine low genotoxicity and immunogenicity with efficient delivery have shown promise. However, numerous delivery challenges must be overcome, including developing techniques to evade preexisting immunity to ensure more efficient transduction of therapeutically relevant cell types, to target delivery, and to ensure genomic maintenance. Fortunately, vector design and development efforts are overcoming these barriers and demonstrating clinical successes. Cambridge Healthtech Institute’s Inaugural Vector Design and Development for Gene and Cell Therapies conference convenes molecular biologists, cell-line developers, process developers, vector engineers, material scientists, synthetic biologists, biochemists, geneticists, immunologists, and virologists from biotech and pharma companies, along with clinicians who are driving the advancement of gene and cell therapies into the clinic.
FEATURED PRESENTATION: Construction of Recombinant Adenovirus Genomes by Direct Cloning
Guangping Gao, PhD, Co-Director, Li Weibo Institute for Rare Diseases Research; Director, Horae Gene Therapy Center and Viral Vector Core; Professor of Microbiology and Physiological Systems, Penelope Booth Rockwell Professor in Biomedical Research, University of Massachusetts Medical School
The Development of Recombinant Adeno-Associated Virus/Human Bocavirus Vector Production System
Ziying Yan, PhD, Research Associate Professor, Department of Anatomy and Cell Biology, The University of Iowa
Engineering Genetic Circuits for Controllable CAR T Immunotherapy
Peter Yingxiao Wang, PhD, Professor, Bioengineering, Department of Bioengineering, Institute of Engineering in Medicine, University of California, San Diego
Multiplex and Clonal Assessment of Production Yield of In Silico Designed AncAAVs
Christopher Tipper, PhD, Director of Discovery Research, Grousbeck Gene Therapy Center, Massachusetts Eye and Ear Infirmary, Schepens Eye Research Institute
* The program is subject to change without notice, due to unforeseen reason.
2020 Conferences & Training Seminars